1-12 of 12
Jan G.J. van De Winkel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells By Combining Therapeutic Antibodies with CD20-Specific Immunoligands Engaging NKG2D or NKp30

Matthias Peipp, PhD, Christian Kellner, PhD, Andreas Günther, MD, Andreas Humpe, MD, Roland Repp, MD, Katja Klausz, PhD, Stefanie Derer, PhD, Thomas Valerius, MD, Jan G.J. van de Winkel, PhD, Paul W.H.I. Parren, PhD, Martin Gramatzki, MD
Journal: Blood
Blood (2014) 124 (21): 1779.
https://doi.org/10.1182/blood.V124.21.1779.1779
Published: 2014
Journal Articles

Mimicking An Induced Self Phenotype by Coating Lymphomas with the Nkp30-Ligand B7-H6 Promotes Antitumoral Natural Killer Cell Cytotoxicity

Christian Kellner, Tina Maurer, Daniela Hallack, Roland Repp, Jan G.J. van de Winkel, Paul W.H.I. Parren, PhD, Andreas Humpe, Martin Gramatzki, Matthias Peipp
Journal: Blood
Blood (2011) 118 (21): 103.
https://doi.org/10.1182/blood.V118.21.103.103
Published: 2011
Journal Articles

Fusion Proteins of Ligands for NKG2D and CD20-Directed ScFvs Sensitize Lymphomas for NK Cell-Mediated Lysis

Christian Kellner, Daniela Hallack, Pia Glorius, Matthias Staudinger, Sahar Mohseni Nodehi, Tina Maurer, Roland Repp, Michel de Weers, Jan G.J. van De Winkel, Paul W.H.I. Parren, Andreas Humpe, Martin Gramatzki, Matthias Peipp
Journal: Blood
Blood (2010) 116 (21): 2843.
https://doi.org/10.1182/blood.V116.21.2843.2843
Published: 2010
Journal Articles

Recombinant Chimeric IgA1 and IgA2 Antibodies for Tumor Immunotherapy.

Michael Dechant, MD, Thomas Beyer, PhD, Stefan Lohse, Tanja Schneider-Merck, PhD, Wencke Weisner, Sven Berger, PhD, Matthias Peipp, PhD, Jan G.J. van de Winkel, PhD, Thomas Valerius, MD
Journal: Blood
Blood (2007) 110 (11): 4892.
https://doi.org/10.1182/blood.V110.11.4892.4892
Published: 2007
Journal Articles

Chemotherapy-Refractory Diffuse Large B-Cell Lymphomas (DLBCL) Are Effectively Killed by Ofatumumab-Induced Complement-Mediated Cytoxicity.

Saskia A.G.M. Cillessen, MSc, Wendy J.M. Mackus, PhD, Kitty C.M. Castricum, Wim Vos, Pim C. Kortman, Jan G.J. van de Winkel, PhD, Paul W.H.I. Parren, PhD, Chris J.L.M. Meijer, PhD, MD, Joost J. Oudejans, PhD, MD, (Intr. by Ole Baadsgaard)
Journal: Blood
Blood (2007) 110 (11): 2346.
https://doi.org/10.1182/blood.V110.11.2346.2346
Published: 2007
Journal Articles

Development of an Effective Safety Switch for Selective Elimination of Human T Cells In Vivo after Adoptive Transfer.

Tom van Meerten, BSc, Henk Rozemuller, PhD, Wendy J.M. Mackus, PhD, Paul W.H.I. Parren, PhD, Jan G.J. van de Winkel, PhD, Marie-Jose Claessen, MSc, Rozemarijn S. van Rijn, MD, Anton Hagenbeek, MD PhD, Anton C.M. Martens, PhD, Saskia B. Ebeling, PhD
Journal: Blood
Blood (2006) 108 (11): 5488.
https://doi.org/10.1182/blood.V108.11.5488.5488
Published: 2006
Journal Articles

Fully Human CD38 Antibodies Efficiently Trigger ADCC of Multiple Myeloma Cell Lines and Primary Tumor Cells.

Matthias Peipp, PhD, Michel de Weers, PhD, Thomas Beyer, PhD, Roland Repp, MD, Paul Parren, PhD, Thomas Valerius, MD, Jan G.J. van de Winkel, PhD
Journal: Blood
Blood (2005) 106 (11): 3377.
https://doi.org/10.1182/blood.V106.11.3377.3377
Published: 2005
Journal Articles

A New Human CD20 Antibody for Improved Killing of CD20-Transgenic T Cells for Allogeneic Stem Cell Transplantation.

Tom van Meerten, PhD, Wendy J.M. Mackus, PhD, Paul W.H.I. Parren, PhD, Jan G.J. van de Winkel, PhD, Anton Hagenbeek, MD, Saskia B. Ebeling, PhD
Journal: Blood
Blood (2005) 106 (11): 5538.
https://doi.org/10.1182/blood.V106.11.5538.5538
Published: 2005
Journal Articles

The FcγRIa (CD64) Ligand Binding Chain Triggers Major Histocompatibility Complex Class II Antigen Presentation Independently of Its Associated FcR γ-Chain

Martine J. van Vugt, Monique J. Kleijmeer, Tibor Keler, Ingrid Zeelenberg, Marc A. van Dijk, Jeanette H.W. Leusen, Hans J. Geuze, Jan G.J. van de Winkel
Journal: Blood
Blood (1999) 94 (2): 808–817.
https://doi.org/10.1182/blood.V94.2.808
Published: 1999
Journal Articles

Human Immunoglobulin A Receptor (FcRI, CD89) Function in Transgenic Mice Requires Both FcR γ Chain and CR3 (CD11b/CD18)

Marjolein van Egmond, A.J. Hanneke van Vuuren, H. Craig Morton, Annemiek B. van Spriel, Li Shen, Frans M.A. Hofhuis, Takashi Saito, Tanya N. Mayadas, J. Sjef Verbeek, Jan G.J. van de Winkel
Journal: Blood
Blood (1999) 93 (12): 4387–4394.
https://doi.org/10.1182/blood.V93.12.4387
Published: 1999
Journal Articles

Heparin-Induced Thrombocytopenia: New Insights Into the Impact of the FcγRIIa-R-H131 Polymorphism

Lena E. Carlsson, Sentot Santoso, Gudrun Baurichter, Hartmut Kroll, Stephanie Papenberg, Petra Eichler, Nomdo A.C. Westerdaal, Volker Kiefel, Jan G.J. van de Winkel, Andreas Greinacher
Journal: Blood
Blood (1998) 92 (5): 1526–1531.
https://doi.org/10.1182/blood.V92.5.1526
Published: 1998
Journal Articles

FcαRI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy

Thomas Valerius, Bernhard Stockmeyer, Annemiek B. van Spriel, Robert F. Graziano, Ingrid E. van den Herik-Oudijk, Roland Repp, Yashwant M. Deo, John Lund, Joachim R. Kalden, Martin Gramatzki, Jan G.J. van de Winkel
Journal: Blood
Blood (1997) 90 (11): 4485–4492.
https://doi.org/10.1182/blood.V90.11.4485
Published: 1997